Madrigal Pharmaceuticals (NASDAQ: MDGL)
Madrigal Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Madrigal Pharmaceuticals Company Info
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
News & Analysis
2 Under-the-Radar Growth Stocks to Consider
Don't ignore these innovative companies.
Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics
These businesses should see good times ahead.
1 No-Brainer Growth Stock to Buy Now
This liver-disease specialist might be significantly undervalued.
Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval?
Could it be just a matter of time before Madrigal Pharmaceuticals stock takes off?
Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock
This biotech just got clearance to dive into a deep ocean of a market.
This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy?
The mid-cap biotech has succeeded where many others failed.
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?
Madrigal has one key advantage over its two huge potential future rivals.
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.